ceo response, page-36

Its easy to prejudge Novogen and its chances. The CEO himself says 98% from this point on fail.

So what does it take to make the 2% cut? Despite this, I think the real question is what MORE could Novogen MK 2 had done to this point. What MORE could it have done from the angle of science and management

At this stage we appear to have all the credentials to avoid the scrapheap. All we have to do for the moment is keep buying a ticket to the next stage, the next milestone and/or the next trial.

I assume that the drug works. Its up to the regulatory bodies to establish benchmarks to prove otherwise. While our CEO makes the tests even tougher, I'll keep the faith.